How two companies sprinted ahead in the extraordinary race for a COVID vaccine

  • 📰 smh
  • ⏱ Reading Time:
  • 54 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 80%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Just as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer chief executive Albert Bourla called on his top vaccine scientists and laid out a clear mission

Add articles to your saved list and come back to them any time.:

"He did not want us to focus on the potential barriers we might face, but instead said that it is much better to try to do something that seemed impossible, and even if you don't succeed, you still have done something great, " said Dormitzer, noting that new vaccine development can cost on the order of $US1 billion .What followed was a full-bore effort carried out under strict coronavirus lockdown conditions, .

In Pfizer's and BioNTech's case, decision-making that normally would take months was reduced to days, including the crucial call on which vaccine version to use in a human clinical trial that has enrolled about 44,000 people worldwide so far. At Novartis AG, Dormitzer began testing novel ways to make vaccines using messenger ribonucleic acid, or mRNA, which contains instructions for human cells. In this case, scientists introduce mRNA instructions for cells to make a portion of a virus, which the immune system recognises as a threat and counters with a protective response. No actual virus is involved in the process.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

understand coronavirus vaccine and the three vaccine candidates now. Coronavirus Vaccines Candidates works only under these conditions.

WE DO NOT NEED A DAMN VIRUS, THERE IS NOTHING NEW TO VAX AGAINST, THE WESTERN MEDIA ARE DANGEROUS PROPAGANDISTS FOR BIG PHARMA

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 6. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인